Publications by authors named "Fernando D Flores-Silva"

Background: Despite the high number of vaccines administered against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, the information on the psychological/psychiatric adverse events following immunization (AEFI) with these newly developed vaccines remains scarce.

Objective: To describe the frequency of psychological/psychiatric symptoms among recipients of five different anti-SARS-CoV-2 vaccines and to explore the factors associated with their development reported in the nationwide Mexican registry of AEFI against SARS-CoV-2.

Methods: Descriptive study of all the psychological/psychiatric symptoms, including anxiety, panic attacks, insomnia, and agitation reported to the Mexican Epidemiological Surveillance System from 21 December 2020 to 27 April 2021, among adult (≥18 years old) recipients of 7,812,845 doses of BNT162b2, ChAdOx1 nCov-19, rAd26-rAd5, Ad5-nCoV, or CoronaVac.

View Article and Find Full Text PDF
Article Synopsis
  • * The study found 97 cases of GBS with an overall incidence of 1.19 per million doses, noting higher risks associated with specific vaccines like Ad26.COV2-S and BNT162b2.
  • * Despite the low incidence, GBS onset typically occurred about 10 days post-vaccination, with a notable proportion of patients requiring significant medical intervention and experiencing severe disability outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • A study analyzed stroke incidents as adverse events following the administration of 79,399,446 doses of six different COVID-19 vaccines in Mexico from December 2020 to August 2021.
  • The research monitored hospitalized adult patients, focusing on types of strokes occurring within 30 days post-vaccination and identified acute ischemic strokes (AIS) as the most common, with a total incidence of 0.71 cases per million doses.
  • Out of 56 stroke cases reported, most occurred shortly after vaccination (median of 2 days), with 48.2% diagnosed within the first 24 hours, highlighting the need for careful monitoring of potential neurological side effects following vaccination.
View Article and Find Full Text PDF

Objectives: The antiphospholipid syndrome (APS) is an autoimmune disease associated with thrombotic and non-thrombotic neurologic manifestations. APS is classified as primary (PAPS) or secondary (SAPS) when it co-exists with another autoimmune disease. We aim to describe the spectrum of acute cerebrovascular disease among patients with APS, their differences between stroke subtypes, and long-term functional outcomes.

View Article and Find Full Text PDF

Background: A high proportion of coronavirus disease 2019 (COVID-19) survivors may develop long-term cognitive impairment. We aimed to develop a multivariate causal model exposing the links between COVID-19-associated biomarkers, illness-related variables, and their effects on cognitive performance.

Methods: In this prospective study, we assess the potential drivers for the development of cognitive impairment in patients with severe COVID-19 pneumonia aged ≥ 18 years at 6-month follow-up after hospital discharge, using the Montreal Cognitive Assessment (MoCA).

View Article and Find Full Text PDF

Background: Intracerebral hemorrhage (ICH) is associated with an ominous outcome influenced by the time to hospital presentation.

Objective: This study aims to identify the factors that influence an early hospital arrival after ICH and the relationship with outcome.

Methods: In this multicenter registry, patients with confirmed ICH on CT scan and well-known time of symptoms onset were studied.

View Article and Find Full Text PDF

mRNA-based COVID-19 vaccines are effective; however, persistent vaccine hesitancy is partly due to a misperception of their potential adverse events. Non-specific sensory symptoms (NSSS) following immunization are thought to be mediated by stress-related responses. In this case-control study, we evaluated NSSS from a cohort of 7,812,845 BNT162b2 first-dose recipients, of whom 10,929 reported an adverse event following immunization (AEFI).

View Article and Find Full Text PDF

With an ever-increasing population of patients recovering form severe coronavirus disease 2019 (COVID-19), recognizing long-standing and delayed neurologic manifestations is crucial. Here, we present a patient developing posterior reversible encephalopathy syndrome (PRES) in the convalescence form severe coronavirus disease 2019 (COVID-19). A 61-year-old woman with severe (COVID-19) confirmed by nasopharyngeal real-time reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) required invasive mechanical ventilation 24-hours after admission.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates "silent hypoxemia" in COVID-19 patients, where individuals experience low oxygen levels without feeling short of breath.
  • Researchers analyzed 470 hospitalized adults with severe hypoxia, finding that only 4.9% presented without dyspnea.
  • Key predictors of silent hypoxemia included new-onset headaches and seeking medical help within eight days of symptom onset, indicating a potential underestimation of disease severity due to lower physiological responses.
View Article and Find Full Text PDF

Background: The coronavirus disease 2019 (COVID-19) pandemic dramatically increased the number of patients requiring treatment in an intensive care unit or invasive mechanical ventilation worldwide. Delirium is a well-known neuropsychiatric complication of patients with acute respiratory diseases, representing the most frequent clinical expression of acute brain dysfunction in critically ill patients, especially in those undergoing invasive mechanical ventilation. Among hospitalized patients with COVID-19, delirium incidence ranges from 11% to 80%, depending on the studied population and hospital setting.

View Article and Find Full Text PDF

Background: The coronavirus disease 2019 (COVID-19) is a systemic entity that frequently implies neurologic features at presentation and complications during the disease course. We aimed to describe the characteristics and predictors for developing in-hospital neurologic manifestations in a large cohort of hospitalized patients with COVID-19 in Mexico City.

Methods: We analyzed records from consecutive adult patients hospitalized from March 15 to June 30, 2020, with moderate to severe COVID-19 confirmed by reverse transcription real-time polymerase chain reaction (rtRT-PCR) for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

View Article and Find Full Text PDF

In severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated disease coronavirus disease 2019 (COVID-19), hypoxemia mechanisms differ from those observed in acute respiratory distress syndrome. Hypoxemia and respiratory failure in COVID- 19 are attributed to pulmonary angiopathy, increasing physiological pulmonary shunting1-3.

View Article and Find Full Text PDF